Navigation Links
BioMarin Announces Fourth Quarter and Full Year 2010 Financial Results
Date:2/17/2011

a non-GAAP adjusted EBITDA measure will be utilized, which is more aligned with management's internal goal setting process.  Non-GAAP information under the previous methodology for the fourth quarter and years ended 2010 and 2009, as well as the new adjusted EBITDA methodology for fiscal 2010 and guidance for 2011 is denoted on page 5 of this press release.  In addition, this non-GAAP adjusted EBITDA information has been provided on a pro-forma basis for the quarters and fiscal years for 2009 and 2010 in Appendix A for information purposes.   Anticipated Upcoming Milestones2Q 2011: Initiation of pivotal Phase III trial for Firdapse for LEMS in the U.S.Mid-2011: Top-line results from PEG-PAL Phase II trial, including daily dosing and formulation studiesLate 2011: 510k approval and commercial availability of the handheld blood Phe monitor for PKU1Q 2012: Initiation of Phase III PEG-PAL trial1Q 2012: Initiation of Phase I trial for BMN-111 for Achondroplasia1H 2012: NDA filing for Firdapse for LEMS in the U.S.2H 2012: Top-line results for Phase III trial for GALNS for MPS IVA2H 2012: Top-line results for PKU-016 Kuvan neurocognitive study4Q 2012: Approval of Firdapse for LEMS in the U.S.4Q 2012: Top-line results for Phase I/II trial for BMN-701 for Pompe disease4Q 2012/1Q 2013: Market authorization application filings for GALNS for MPS IVAResearch and Development ProgramsBioMarin continues to make significant investments in research and development to ensure continued growth of the company.  The current pipeline includes programs in various stages of development and is focused on treating a range of serious unmet medical needs.Advanced Clinical Programs

  • GALNS for MPS IVA: BioMarin initiated a randomized, double-blind, placebo-controlled Phase III study in early February 2011 with primary endpoint of six-minute walk distance, 24 weeks in treatment duration and treatment doses of two mg/kg/week and two mg/kg/every other week.  
    '/>"/>

  • SOURCE BioMarin Pharmaceutical Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

    Related medicine technology :

    1. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
    2. BioMarin to Host Fourth Quarter and Full Year 2010 Financial Results
    3. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
    4. BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers
    5. BioMarin to Present at the J.P. Morgan 29th Annual Healthcare Conference
    6. BioMarin to Present at the Deutsche Bank 2010 BioFEST Conference
    7. BioMarin Completes Partial Exchange of Convertible Notes Due 2013 for Common Stock
    8. BioMarin Announces Third Quarter 2010 Financial Results
    9. BioMarin to Host a Research and Development Day on October 19th
    10. BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
    11. BioMarin to Present at the UBS Global Life Sciences Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... Directors has approved a share repurchase program. The open-ended ... million of Mallinckrodt plc ordinary shares. ... remain top priorities as we continue to pursue a ...
    (Date:1/23/2015)... LONDON and BOSTON , January ... structure-guided drug discovery and development company, is delighted to announce ... has been awarded to Miles Congreve (Vice President ... co-founder) and Malcolm Weir (Chief Executive Officer and ...
    (Date:1/22/2015)... a privately held medical device company, announced today that ... ITOCHU Corporation (Tokyo Stock Exchange TYO: 8001) to sell ... cancer in Japan . ViewRay,s technology, ... only MRI-guided radiation therapy system that images and treats ...
    Breaking Medicine Technology:Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2
    ... SWANTON, Vt ., May 7 This May, AllerAir ... their effort to spread Multiple Chemical Sensitivity Syndrome awareness.   , ... AllerAir will make chemical awareness tips ... www.allerair.com .  Additionally, their blogs and articles ...
    ... A post-hoc analysis of a Phase 3 safety study ... a lower incidence of nausea, vomiting and constipation when compared ... moderate to severe low-back or osteoarthritis pain.  These data will ... Annual Scientific Meeting of the American Pain Society (APS), and ...
    Cached Medicine Technology:Multiple Chemical Sensitivities Are Real 2Multiple Chemical Sensitivities Are Real 3Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 2Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 3Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 4Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 5Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 6Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 7Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 8Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 9
    (Date:1/22/2015)... January 22, 2015 The City of West Hollywood ... a.m., to commemorate the 42nd anniversary of the Supreme Court decision ... “It’s been 42 years since the Roe vs. Wade decision and ... as present as ever,” said City of West Hollywood Councilmember Abbe ...
    (Date:1/22/2015)... 22, 2015 The Incredible Bulk is a ... to increase lean muscle by up to 30lbs in less ... attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , ... a step-by-step, scientific diet formula that allows the body to ...
    (Date:1/22/2015)... (PRWEB) January 22, 2015 Juvent Sports ... at the 2015 PGA Merchandise Show to bestow a ... incredible female amateur golfer, Arlene McKitrick. The award commemorated ... amateur golf tournament win. She won her first amateur ...
    (Date:1/22/2015)... has released a new blog post presenting the basic features ... Purchasing an accidental death and dismemberment rider for a car ... provides benefits if the insured dies in an accident. Accidental ... life insurance. , AD&D is not expensive and can ...
    (Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and ... to treat specific body parts and muscle groups. , ... to use patented cold therapy machine with the innovative IsoTube ... muscle injuries. IsoComforter has become the industry leader in ...
    Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
    ... 18 Smart Balance Inc.,(Nasdaq: SMBL ) announced ... the annual Citi Small/Midcap Conference in Las Vegas, NV, ... Steven Hughes, Chairman and Chief Executive Officer and Alan ... to,investors at the conference as well as through the ...
    ... only a few centers in Canada that perform living donor ... that expands the organ donor pool. About 80 liver transplants ... living-donor. , All potential liver transplant donors are assessed based ... liver and vascular and bile duct anatomy. Thanks to a ...
    ... March 18 The Comprehensive Eating,Disorders Program at ... treat young adults ages 18 to 21. This ... adolescents and college students., "I am delighted ... to our undergraduate age group," said Naomi Brown, ...
    ... VASCULAR BENEFITS FROM EXERCISE , Overweight but active ... in a first-of-its kind study from Indiana University that ... , Vascular function is important because of its ... saw an average 24 percent improvement in their vascular ...
    ... 80 and older may not need to be hospitalized, ... People over 80 can safely have diagnostic radiology tests ... for their safety, a new study finds. , "The ... but also drug trials, might not be safe for ...
    ... ACM, one of the country,s leading,healthcare ... Plans, Inc. today announced a new agreement ... pricing precision to medical,pharmacy infusion services provided ... a decade, ACM,s e-Precision Claims(SM) technology has ...
    Cached Medicine News:Health News:Smart Balance to Webcast Presentation at Citi Small/Midcap Conference 2Health News:Eating Disorders Program at Lucile Packard Children's Hospital Expands to Include Young Adults 2Health News:Eating Disorders Program at Lucile Packard Children's Hospital Expands to Include Young Adults 3Health News:IU Health & Wellness: Research and insights from Indiana University 2Health News:IU Health & Wellness: Research and insights from Indiana University 3Health News:IU Health & Wellness: Research and insights from Indiana University 4Health News:The Elderly Can Be Candidates for Angioplasty, Stenting 2Health News:ACM Partners With Tufts Associated Health Plans to Improve the Cost-effective Delivery of Home Infusion Services 2
    ... 2000 apparatus and ready-to-use gels are the ... of nucleic acids by submerged gel electrophoresis. ... system, offering full compatibility and optimal performance, ... SEA 2000 and a unique staining tray, ...
    ... offer many advantages for nucleic acid separation, ... the molecular biologist. Agarose gels are easy ... gels allow sample underlaying and prevent electrical ... well dehydration. Horizontal systems are more economical ...
    Mini ReadySub-Cell GT Cell, includes buffer tank, lid and electrodes, leveling bubble; accommodates 8-well and 12-well mini ReadyAgarose gels...
    The Large Gel Drying Kit dries gels using the same principal components as the DryEase Mini-Gel Drying System but can accommodate larger format gels or four mini-gels. A base is not required for asse...
    Medicine Products: